Iridium-Binding Peptide Sequence and Biotin-PEG Modification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for a novel peptide capable of binding to iridium, as existing peptides do not effectively recognize or interact with this element.

Innovation Solution

A peptide with a specific amino acid sequence (SQMMGHMGHGNMNHMNHGGKFDFHH) is developed, which is derived from the amino acid sequence of CueO, a multi-copper oxidase from Escherichia coli K-12, and is chemically modified with biotin-polyethylene glycol to enhance its binding capabilities to iridium nanoparticles.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing peptides are used, then the peptide structure is simple, but the binding ability to iridium is insufficient

Engineering Contradiction:

Improvebinding ability to iridiumVSAvoidpeptide structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent modifies the peptide sequence parameters by incorporating specific amino acid residues (His, Met, Cys) at defined positions to enhance iridium binding affinity. The sequence SQMMGHMGHGNMNHMNHGGKFDFHH contains strategically placed metal-binding residues that change the chemical properties of the peptide to improve iridium interaction

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite structure by combining the peptide with biotin-polyethylene glycol modification. This composite approach integrates the iridium-binding peptide sequence with biotin for potential avidin-mediated applications, enhancing both binding capability and functional versatility

Inventive Principle:

Principle #40Composite materials

2Reliability

If the peptide is chemically modified with biotin-polyethylene glycol, then the binding capability to iridium is enhanced, but the manufacturing process becomes more complex

Engineering Contradiction:

Improvebinding capability to iridiumVSAvoidchemical modification process

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The peptide sequence is designed with pre-positioned amino acid residues (His, Met, Cys) that are optimized for iridium binding before any chemical modification occurs. This preliminary optimization of the core sequence ensures high binding affinity is achieved at the design stage, reducing the complexity burden of subsequent biotin-PEG modification

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The biotin-polyethylene glycol acts as an intermediary modification that attaches to the N-terminus of the peptide without interfering with the iridium-binding residues. This modular approach allows the binding function and the modification function to be separated, simplifying the overall manufacturing strategy

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS8674067B2Peptide capable for binding to iridium

Publication Date: 2014.03.18 PANASONIC HOLDINGS CORP

AI summary

The present invention provides a novel peptide capable for binding to iridium. The peptide consists of an amino acid sequence represented by SQMMGHMGHGNMNHMNHGGKFDFHH (SEQ ID NO: 01).